Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Oscar Health Inc (NYSE: OSCR) closed at $19.28 up 2.01% from its previous closing price of $18.9. In other words, the price has increased by $2.01 from its previous closing price. On the day, 17.84 million shares were traded. OSCR stock price reached its highest trading level at $20.03 during the session, while it also had its lowest trading level at $18.8.
Ratios:
For a deeper understanding of Oscar Health Inc’s stock, let’s take a closer look at its various ratios. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.26.
On July 15, 2025, UBS Downgraded its rating to Sell which previously was Neutral but kept the price unchanged to $11.
Piper Sandler Downgraded its Overweight to Neutral on July 14, 2025, while the target price for the stock was maintained at $14.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 22 ’25 when Schlosser Mario sold 395,000 shares for $18.43 per share. The transaction valued at 7,279,850 led to the insider holds 501,148 shares of the business.
MARIO T SCHLOSSER bought 395,000 shares of OSCR for $7,280,996 on Sep 22 ’25. On Jun 20 ’25, another insider, RANMALI BOPITIYA, who serves as the Officer of the company, bought 30,000 shares for $18.77 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OSCR now has a Market Capitalization of 4985002496 and an Enterprise Value of 1802043008. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.46 while its Price-to-Book (P/B) ratio in mrq is 4.30. Its current Enterprise Value per Revenue stands at 0.168 whereas that against EBITDA is -18.197.
Stock Price History:
The Beta on a monthly basis for OSCR is 1.89, which has changed by -0.042701066 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, OSCR has reached a high of $22.78, while it has fallen to a 52-week low of $11.20. The 50-Day Moving Average of the stock is 14.33%, while the 200-Day Moving Average is calculated to be 25.63%.
Shares Statistics:
For the past three months, OSCR has traded an average of 25.18M shares per day and 16012530 over the past ten days. A total of 222.91M shares are outstanding, with a floating share count of 189.35M. Insiders hold about 26.77% of the company’s shares, while institutions hold 55.92% stake in the company. Shares short for OSCR as of 1757894400 were 34579578 with a Short Ratio of 1.37, compared to 1755216000 on 57679570. Therefore, it implies a Short% of Shares Outstanding of 34579578 and a Short% of Float of 17.24.
Earnings Estimates
Current recommendations for the stock of the company come from 7.0 analysts. The consensus estimate for the next quarter is -$0.98, with high estimates of -$0.85 and low estimates of -$1.18.
Analysts are recommending an EPS of between -$1.01 and -$1.91 for the fiscal current year, implying an average EPS of -$1.38. EPS for the following year is -$0.32, with 7.0 analysts recommending between $0.16 and -$1.06.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $3.09B this quarter.It ranges from a high estimate of $3.13B to a low estimate of $3.05B. As of. The current estimate, Oscar Health Inc’s year-ago sales were $2.42BFor the next quarter, 7 analysts are estimating revenue of $3.06B. There is a high estimate of $3.09B for the next quarter, whereas the lowest estimate is $3.03B.
A total of 7 analysts have provided revenue estimates for OSCR’s current fiscal year. The highest revenue estimate was $12.11B, while the lowest revenue estimate was $11.99B, resulting in an average revenue estimate of $12.06B. In the same quarter a year ago, actual revenue was $9.18BBased on 7 analysts’ estimates, the company’s revenue will be $11.31B in the next fiscal year. The high estimate is $12.13B and the low estimate is $10.9B.
